[Rationale for the use of liposomal cytarabine in meningeal carcinomatosis].
Neuroscienze Cliniche, UO Neurologia II Neuroncologia, Istituto Nazionale Neurologico Carlo Besta, Milano.
Amerigo
A
Boiardi
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002277:Carcinoma / Q000150:complications / Q000188:drug therapy*; D003561:Cytarabine / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D006801:Humans; D007276:Injections, Intraventricular / Q000295:instrumentation; D007278:Injections, Spinal; D008081:Liposomes; D008581:Meningitis / Q000188:drug therapy* / Q000209:etiology
D000964:Antimetabolites, Antineoplastic; D003692:Delayed-Action Preparations; D008081:Liposomes; D003561:Cytarabine